Camp4 Therapeutics CORP

CAMP4 Therapeutics announced the second closing of its private placement, raising approximately $50.1 million to advance its CMP-002 program for SYNGAP1-related disorder.

CAMP4 Therapeutics receives Australian regulatory clearance to initiate its Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder, and is eligible for up to $50 million in additional funding.

CAMP4 Therapeutics announced new preclinical data showing CMP-002 significantly improves seizure phenotypes in a SYNGAP1-related disorder mouse model, advancing towards a Phase 1/2 trial.

CAMP4 Therapeutics announced first quarter 2026 financial results, highlighting significant progress in its CMP-002 clinical development and a cash runway extending into 2028.

CAMP4 Therapeutics Corporation announced the appointment of Michael MacLean, a seasoned financial leader in the biotechnology industry, as a Class III director, effective April 1, 2026.

CAMP4 Therapeutics announced full year 2025 financial results, highlighted progress in its SYNGAP1 program, a new strategic collaboration with GSK, and strengthened its balance sheet with new financing extending its cash runway into 2028.

CAMP4 Therapeutics reports increased collaboration revenue in Q1 2026, but a wider net loss driven by derivative liability revaluation.

CAMP4 Therapeutics reported increased cash reserves and collaboration revenue in its Q3 2025 filing, driven by a recent private placement, while pausing new investment in its UCD program.

CAMP4 Therapeutics Corporation reported a net loss of $12.6 million for Q2 2025, with cash reserves projected to last only into Q2 2026, raising substantial doubt about its ability to continue as a going concern.

CAMP4 Therapeutics reports a net loss of $12.4 million for Q1 2025 and anticipates current cash reserves will fund operations into Q2 2026.

CAMP4 Therapeutics Corporation reported its financial results for the third quarter of 2024, highlighting ongoing clinical development efforts and financial updates.

CAMP4 Therapeutics reported a significant increase in net losses for 2025, reaching $80.4 million, while advancing its lead SYNGAP1 therapeutic and securing new funding and collaborations.

CAMP4 Therapeutics reports its full year 2024 financial results and provides an update on its clinical and preclinical programs, including the ongoing Phase 1 trial for CMP-CPS-001.

Director Douglas E. Williams was granted 28,000 stock options in Camp4 Therapeutics Corp.

Camp4 Therapeutics Director Steven H Holtzman acquired 28,000 stock options with an exercise price of $4.34, vesting on the earlier of one year or the next annual meeting.

Camp4 Therapeutics Director Stewart Murray acquired 28,000 stock options at $4.34 per share, vesting over one year.

Camp4 Therapeutics Director and 10% owner Amir Nashat acquired 28,000 stock options with an exercise price of $4.34.

Daniel Tardiff, Chief Scientific Officer at Camp4 Therapeutics Corp, was granted a stock option for 170,000 shares.

Yuri Maricich, Chief Medical Officer of Camp4 Therapeutics Corp, was granted stock options for 215,000 shares.

CAMP4 Therapeutics Corporation announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026, with key proposals including director elections and an amendment to its equity incentive plan.

Camp4 Therapeutics Corporation has filed a definitive proxy statement with the SEC regarding its upcoming 2025 annual meeting.

CAMP4 Therapeutics Corporation will hold its 2025 annual meeting of stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.

CAMP4 Therapeutics is seeking to raise capital through an initial public offering to advance its regulatory RNA-based therapeutics pipeline.

CAMP4 Therapeutics is planning an initial public offering to fund its regulatory RNA-based therapeutics development.

CAMP4 Therapeutics is seeking to go public to fund the development of its regulatory RNA-based therapeutics, initially targeting urea cycle disorders and SYNGAP1-related disorders.

Enavate Sciences GP and Everest Aggregator have reduced their beneficial ownership in CAMP4 Therapeutics Corporation to 6.0% through recent open market sales.

Enavate Sciences and Everest Aggregator report a diluted beneficial ownership of 8.1% in CAMP4 Therapeutics Corporation following a private placement, alongside a director's resignation.

Polaris Partners and affiliated entities increased their beneficial ownership in Camp4 Therapeutics to 8.4% following a $50.1 million private placement.

5AM Ventures and affiliates increased their beneficial ownership in CAMP4 Therapeutics to 12.5% through a $4.5 million initial private placement.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.07% of Camp4 Therapeutics Corp. common stock as of March 31, 2026.

Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed a combined beneficial ownership of 7.4% in Camp4 Therapeutics Corp, as reported in a Schedule 13G filing.

FMR LLC and Abigail P. Johnson have reported a 9.5% beneficial ownership stake in CAMP4 Therapeutics Corporation as of December 31, 2025.

Janus Henderson Group plc has reported a 12.2% beneficial ownership stake in CAMP4 THERAPEUTICS CORP, as detailed in a recent Schedule 13G filing.

Coastlands Capital LP filed an amendment to its Schedule 13G for Camp4 Therapeutics Corp, correcting a rounding error in its reported 9.99% beneficial ownership.

AH Bio Funds and managing members Marc Andreessen and Benjamin Horowitz report beneficial ownership of 4.5% of CAMP4 THERAPEUTICS CORPORATION common stock.